Roche’s hunt for better eye disease gene therapy vectors has led to Avista Therapeutics. In a heavily backloaded deal, the Swiss Big Pharma has offered up $1 billion to secure the right to assess and ...
In recent years, we have seen rapid growth in the development of adeno-associated virus (AAV)-mediated gene therapy products that target fatal and highly debilitating diseases. Growth is evident in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results